{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/fungal-skin-infection-body-groin/","result":{"data":{"firstChapter":{"id":"f9a7dce7-311f-5a13-b2c1-c8cd43e2838e","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field bfc71d94-f264-45a5-94fc-006771bdcc3d --><h1>Fungal skin infection - body and groin: Summary</h1><!-- end field bfc71d94-f264-45a5-94fc-006771bdcc3d -->","htmlStringContent":"<!-- begin item 43560064-4729-47e7-897c-0580e7810348 --><!-- begin field b2aaa15a-a5af-4705-8277-5cc88f4c4354 --><ul><li>Fungal infections of the body and groin are also known as 'tinea corporis', and 'tinea cruris' respectively, and describe superficial skin infections predominantly caused by dermatophytes such as Trichophyton rubrum.<ul><li>Fungal groin infection is usually caused by autoinoculation from infection of the hands, feet, or nails.</li></ul></li><li>Risk factors for developing infection include hot humid environments; wearing tight-fitting clothing; obesity; and hyperhidrosis.</li><li>The diagnosis of suspected fungal infection of the body and groin should be made on the basis of clinical features:<ul><li>There may be scaly, itchy skin.</li><li>There may be single or multiple red or pink, flat or slightly raised annular (ring-shaped) patches of varying sizes which enlarge outwards on the body. Typically, lesions have an active red, scaly advancing edge and a clear central area.</li><li>There may be groin involvement of the inguinal folds and proximal medial thighs. The typical scaly edge of lesions may be lost in moist flexures.</li></ul></li><li>Assessment of suspected fungal infection of the body and groin should include:<ul><li>Asking about the nature, site, and duration of any symptoms; previous treatments; family or close contacts affected; and any co-morbidities.</li><li>Examining the person to assess the pattern, extent, and severity of infection, and for any associated inflammation or fungal infection at other sites.</li><li>Arranging for skin sampling for fungal microscopy and culture, if there is severe or extensive disease in adults, or the diagnosis is uncertain.</li></ul></li><li>Initial management of fungal infection of the body and groin should include:<ul><li>Advice on self-care strategies and sources of information.</li><li>Advice on treatment with a topical antifungal cream such as terbinafine or an imidazole if there is mild, non-extensive disease in children and adults.</li><li>Prescribing a short-term mildly-potent topical corticosteroid such as hydrocortisone cream in addition, if there is associated marked inflammation.</li><li>Considering prescribing an oral antifungal such as terbinafine first-line if an adult has severe or extensive disease, depending on fungal microscopy or culture results and/or clinical judgement. Alternative options are oral itraconazole or oral griseofulvin, if terbinafine is not tolerated or is contraindicated.</li><li>Managing concomitant fungal nail, foot, or hand infection, if present, to reduce the risk of reinfection.</li></ul></li><li>If there are persistent signs of infection following topical antifungal treatment in adults:<ul><li>Any underlying cause of treatment failure should be managed, such as non-adherence to self-care advice or the treatment regimen; reinfection from close contacts; or tinea incognito resulting from inappropriate use of topical corticosteroids.</li><li>Skin sampling for fungal microscopy and culture should be arranged.</li><li>Oral antifungal treatment should be prescribed depending on microscopy or culture results and/or clinical judgement.</li></ul></li><li>Referral to a dermatology specialist should be arranged, the urgency depending on clinical judgement, if:<ul><li>There is severe or extensive disease, or topical antifungal treatment is unsuccessful in a child.</li><li>The diagnosis is uncertain.</li><li>Treatment in primary care is unsuccessful or there are frequent recurrences.</li><li>The person is immunocompromised, depending on clinical judgement.</li></ul></li></ul><!-- end field b2aaa15a-a5af-4705-8277-5cc88f4c4354 --><!-- end item 43560064-4729-47e7-897c-0580e7810348 -->","topic":{"id":"10689662-2594-5bc5-aacc-6f0297698637","topicId":"0a9103d8-0e5e-4e22-8ed1-df6caa2888c6","topicName":"Fungal skin infection - body and groin ","slug":"fungal-skin-infection-body-groin","aliases":[],"chapters":[{"id":"f9a7dce7-311f-5a13-b2c1-c8cd43e2838e","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"38743423-24de-522e-95bd-4e728ae9bff6","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"1f4590f4-eb5c-5ac7-ae22-883e2e53a6ad","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"9df03477-c55a-5aee-a960-67b35e299585","slug":"changes","fullItemName":"Changes"},{"id":"ef4d507c-dbca-5b25-8c50-9054ba69b8a6","slug":"update","fullItemName":"Update"}]},{"id":"6a5be767-a22b-5a75-9497-6b23cdd8af40","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"3333af1c-9f09-5390-98b9-e6486fea24ad","slug":"goals","fullItemName":"Goals"},{"id":"181bd2da-6331-5aa0-a497-5c0924b85b3d","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"997df680-1de7-5ca8-bd57-bfdc04fc5708","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4c32deb8-71c7-5ff4-8ea7-21d5afcf46f0","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"291e3f39-4ba8-5287-b429-ab9096f614d1","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"7b7795b7-aa4b-5d16-9865-1f78a9aa7100","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"aa83eccd-4445-5d6a-85eb-2ec1398484cd","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"2993ff5f-d929-5124-b985-8bfe992b6123","slug":"definition","fullItemName":"Definition"},{"id":"e4bd4185-0aa9-5252-9ab8-9db4872de8e3","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"3b35bce6-3614-5272-b2bc-7dfec9933540","slug":"prevalence","fullItemName":"Prevalence"},{"id":"c9f8364f-4629-5bf0-9e81-6b5bc8fa4dc9","slug":"complications","fullItemName":"Complications"},{"id":"db007724-80ee-5dd6-bb25-70aa7c0fa306","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"ddd3b119-1a06-5a24-a5c0-5bd1bdf86d33","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"a8efce2f-87d2-504f-a1d5-92cbd6d2e262","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"aa17d36a-2510-5bdd-b47b-2b2182e55fb9","slug":"assessment","fullItemName":"Assessment"},{"id":"625c3efb-8f3e-5c3f-9743-9fb04531f418","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"ad2cfebe-3930-561d-8516-fccbfb956fbb","slug":"management","fullItemName":"Management","subChapters":[{"id":"058eae7f-c108-5ee2-9421-bce49270bd1d","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"33c2524f-5b03-5298-b8b3-38f522d33ee3","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"3f5f1a54-036e-5ade-823a-9bc062fe3b65","slug":"topical-antifungals","fullItemName":"Topical antifungals"},{"id":"eb246451-6fc8-5e1c-af81-c0780be4ee3f","slug":"oral-terbinafine","fullItemName":"Oral terbinafine"},{"id":"118430c7-7a53-56e6-a43c-ee7b3140563a","slug":"oral-itraconazole","fullItemName":"Oral itraconazole"},{"id":"0a620672-cf78-5a49-83c9-b25a3860e2b9","slug":"oral-griseofulvin","fullItemName":"Oral griseofulvin"}]},{"id":"6118e788-fa21-5752-864e-3f16ec7b305d","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"bd6404d9-1abd-5cf0-99ee-b22f9fd18a84","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"b7837228-7495-51a3-8ea2-973b7ec42868","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"9bbac54b-39fb-522f-bfc7-ce8158baf074","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3c0e56a8-bb2e-5a9e-acbf-0fd43dda553c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f92ac5d0-593d-5b61-887b-d0be3a924870","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"ececdb26-b868-5c5c-834a-dd5d3bdef118","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"ab97556e-8246-5384-b5eb-167898e7b53d","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"10689662-2594-5bc5-aacc-6f0297698637","topicId":"0a9103d8-0e5e-4e22-8ed1-df6caa2888c6","topicName":"Fungal skin infection - body and groin ","slug":"fungal-skin-infection-body-groin","aliases":[],"topicSummary":"Fungal infection of the skin (also known as ringworm or tinea) is caused by dermatophytes.","lastRevised":"Last revised in May 2018","nextPlannedReviewBy":"2023-05-01T00:00:00+01:00","nextPlannedReviewByDateTime":"2023-04","nextPlannedReviewByDisplay":"April 2023","specialities":[{"id":"e174a859-759f-5b1d-898e-1a4155645e13","name":"Infections and infestations","slug":"infections-infestations"},{"id":"50071c38-ab10-5ab8-ac70-6bd19a96c24e","name":"Skin and nail","slug":"skin-nail"}],"chapters":[{"id":"f9a7dce7-311f-5a13-b2c1-c8cd43e2838e","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"38743423-24de-522e-95bd-4e728ae9bff6","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"1f4590f4-eb5c-5ac7-ae22-883e2e53a6ad","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"9df03477-c55a-5aee-a960-67b35e299585","slug":"changes","fullItemName":"Changes"},{"id":"ef4d507c-dbca-5b25-8c50-9054ba69b8a6","slug":"update","fullItemName":"Update"}]},{"id":"6a5be767-a22b-5a75-9497-6b23cdd8af40","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"3333af1c-9f09-5390-98b9-e6486fea24ad","slug":"goals","fullItemName":"Goals"},{"id":"181bd2da-6331-5aa0-a497-5c0924b85b3d","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"997df680-1de7-5ca8-bd57-bfdc04fc5708","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4c32deb8-71c7-5ff4-8ea7-21d5afcf46f0","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"291e3f39-4ba8-5287-b429-ab9096f614d1","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"7b7795b7-aa4b-5d16-9865-1f78a9aa7100","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"aa83eccd-4445-5d6a-85eb-2ec1398484cd","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"2993ff5f-d929-5124-b985-8bfe992b6123","slug":"definition","fullItemName":"Definition"},{"id":"e4bd4185-0aa9-5252-9ab8-9db4872de8e3","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"3b35bce6-3614-5272-b2bc-7dfec9933540","slug":"prevalence","fullItemName":"Prevalence"},{"id":"c9f8364f-4629-5bf0-9e81-6b5bc8fa4dc9","slug":"complications","fullItemName":"Complications"},{"id":"db007724-80ee-5dd6-bb25-70aa7c0fa306","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"ddd3b119-1a06-5a24-a5c0-5bd1bdf86d33","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"a8efce2f-87d2-504f-a1d5-92cbd6d2e262","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"aa17d36a-2510-5bdd-b47b-2b2182e55fb9","slug":"assessment","fullItemName":"Assessment"},{"id":"625c3efb-8f3e-5c3f-9743-9fb04531f418","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"ad2cfebe-3930-561d-8516-fccbfb956fbb","slug":"management","fullItemName":"Management","subChapters":[{"id":"058eae7f-c108-5ee2-9421-bce49270bd1d","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"33c2524f-5b03-5298-b8b3-38f522d33ee3","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"3f5f1a54-036e-5ade-823a-9bc062fe3b65","slug":"topical-antifungals","fullItemName":"Topical antifungals"},{"id":"eb246451-6fc8-5e1c-af81-c0780be4ee3f","slug":"oral-terbinafine","fullItemName":"Oral terbinafine"},{"id":"118430c7-7a53-56e6-a43c-ee7b3140563a","slug":"oral-itraconazole","fullItemName":"Oral itraconazole"},{"id":"0a620672-cf78-5a49-83c9-b25a3860e2b9","slug":"oral-griseofulvin","fullItemName":"Oral griseofulvin"}]},{"id":"6118e788-fa21-5752-864e-3f16ec7b305d","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"bd6404d9-1abd-5cf0-99ee-b22f9fd18a84","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"b7837228-7495-51a3-8ea2-973b7ec42868","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"9bbac54b-39fb-522f-bfc7-ce8158baf074","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3c0e56a8-bb2e-5a9e-acbf-0fd43dda553c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f92ac5d0-593d-5b61-887b-d0be3a924870","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"ececdb26-b868-5c5c-834a-dd5d3bdef118","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"ab97556e-8246-5384-b5eb-167898e7b53d","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"10689662-2594-5bc5-aacc-6f0297698637"}},"staticQueryHashes":["3666801979"]}